Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial
Clinical Immunology, Volume 169, Year 2016
Notification
URL copied to clipboard!
Description
Immunogenicity and safety of different adjuvants combined with a model antigen (HBsAg) were compared. Healthy HBV-naïve adults were randomized to receive HBs adjuvanted with alum or Adjuvant Systems AS01B, AS01E, AS03A or AS04 at Days 0 and 30. Different frequencies of HBs-specific CD4. + T cells 14 days post dose 2 but similar polyfunctionality profiles were induced by the different adjuvants with frequencies significantly higher in the AS01B and AS01E groups than in the other groups. Antibody concentrations 30 days post-dose 2 were significantly higher in AS01B, AS01E and AS03A than in other groups. Limited correlations were observed between HBs-specific CD4. + T cell and antibody responses. Injection site pain was the most common solicited local symptom and was more frequent in AS groups than in alum group. Different adjuvants formulated with the same antigen induced different adaptive immune responses and reactogenicity patterns in healthy naïve adults. The results summary for this study (GSK study number 112115 - NCT# NCT00805389) is available on the GSK Clinical Study Register and can be accessed at www.gsk-clinicalstudyregister.com. © 2016 The Authors.
Authors & Co-Authors
Leroux-Roels, Geert G.
Belgium, Ghent
Universitair Ziekenhuis Gent
Marchant, Arnaud
Belgium, Brussels
Université Libre de Bruxelles
Lévy, Jack A.
Belgium, Brussels
Université Libre de Bruxelles
Van-Damme, Pierre A.
Belgium, Antwerpen
Universiteit Antwerpen
Schwarz, Tino Francis
Germany, Wurzburg
Stiftung Juliusspital
Horsmans, Y.
Belgium, Brussels
Cliniques Universitaires Saint-luc
Jilg, Wolfgang
Germany, Regensburg
Universität Regensburg
Kremsner, Peter G.
Germany, Tubingen
Universitätsklinikum Und Medizinische Fakultät Tübingen
Clément, Frédéric
Belgium, Ghent
Universitair Ziekenhuis Gent
Gabor, Julian Justin
Germany, Tubingen
Universitätsklinikum Und Medizinische Fakultät Tübingen
Esen, Meral
Germany, Tubingen
Universitätsklinikum Und Medizinische Fakultät Tübingen
Fissette, Laurence A.
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
Tavares-Da-Silva, Fernanda
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
Burny, Wivine
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
Janssens, Michel Etienne
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
Moris, Philippe J.
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
Didierlaurent, Arnaud M.
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
van der Most, Robbert G.
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
Garçon, Nathalie M.J.
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
France, Lyon
Bioaster, France
Statistics
Citations: 80
Authors: 19
Affiliations: 9
Identifiers
Doi:
10.1016/j.clim.2016.05.007
ISSN:
15216616